CRISPR Therapeutics AG — Director's Dealing 2023

Mar 14, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2023-03-10

Reporting Person: Morrow Phuong Khanh (Chief Medical Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-03-10	Stock Option (Right to Buy)	$43.22	A	44620	Acquired	2033-03-10	Common Shares (44620)	Direct
2023-03-10	Restricted Stock Units	$	A	22000	Acquired		Common Shares (22000)	Direct

Footnotes

F1: This option was granted on March 10, 2023 with respect to 44,620 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 10, 2023.

F2: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

F3: This restricted stock unit award was granted on March 10, 2023 with respect to 22,000 Common Shares, with (i) one quarter of the shares vesting on March 10, 2024, (ii) one quarter of the shares vesting on March 10, 2025, (iii) one quarter of the shares vesting on March 10, 2026, and (iv) one quarter of the shares vesting on March 10, 2027.